213 related articles for article (PubMed ID: 15149035)
21. Bordetella pertussis pertactin knock-out strains reveal immunomodulatory properties of this virulence factor.
Hovingh ES; Mariman R; Solans L; Hijdra D; Hamstra HJ; Jongerius I; van Gent M; Mooi F; Locht C; Pinelli E
Emerg Microbes Infect; 2018 Mar; 7(1):39. PubMed ID: 29559630
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study.
Jahnmatz M; Richert L; Al-Tawil N; Storsaeter J; Colin C; Bauduin C; Thalen M; Solovay K; Rubin K; Mielcarek N; Thorstensson R; Locht C;
Lancet Infect Dis; 2020 Nov; 20(11):1290-1301. PubMed ID: 32687804
[TBL] [Abstract][Full Text] [Related]
23. Genetic Variation of Bordetella pertussis in Austria.
Wagner B; Melzer H; Freymüller G; Stumvoll S; Rendi-Wagner P; Paulke-Korinek M; Repa A; Mooi FR; Kollaritsch H; Mittermayer H; Kessler HH; Stanek G; Steinborn R; Duchêne M; Wiedermann U
PLoS One; 2015; 10(7):e0132623. PubMed ID: 26182210
[TBL] [Abstract][Full Text] [Related]
24. Proteomics of Bordetella pertussis whole-cell and acellular vaccines.
Möller J; Kraner ME; Burkovski A
BMC Res Notes; 2019 Jun; 12(1):329. PubMed ID: 31182148
[TBL] [Abstract][Full Text] [Related]
25. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.
Feunou PF; Ismaili J; Debrie AS; Huot L; Hot D; Raze D; Lemoine Y; Locht C
Vaccine; 2008 Oct; 26(45):5722-7. PubMed ID: 18762220
[TBL] [Abstract][Full Text] [Related]
26. A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers.
Thorstensson R; Trollfors B; Al-Tawil N; Jahnmatz M; Bergström J; Ljungman M; Törner A; Wehlin L; Van Broekhoven A; Bosman F; Debrie AS; Mielcarek N; Locht C
PLoS One; 2014; 9(1):e83449. PubMed ID: 24421886
[TBL] [Abstract][Full Text] [Related]
27. Bordetella pertussis evolution in the (functional) genomics era.
Belcher T; Preston A
Pathog Dis; 2015 Nov; 73(8):ftv064. PubMed ID: 26297914
[TBL] [Abstract][Full Text] [Related]
28. Non-specific Effects of Live Attenuated Pertussis Vaccine Against Heterologous Infectious and Inflammatory Diseases.
Cauchi S; Locht C
Front Immunol; 2018; 9():2872. PubMed ID: 30581436
[No Abstract] [Full Text] [Related]
29. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis.
Mielcarek N; Riveau G; Remoué F; Antoine R; Capron A; Locht C
Nat Biotechnol; 1998 May; 16(5):454-7. PubMed ID: 9592394
[TBL] [Abstract][Full Text] [Related]
30. Evolution of Bordetella pertussis.
He Q
Pediatr Infect Dis J; 2016 Aug; 35(8):915-7. PubMed ID: 27213264
[No Abstract] [Full Text] [Related]
31. Cross-species protection mediated by a Bordetella bronchiseptica strain lacking antigenic homologs present in acellular pertussis vaccines.
Sukumar N; Sloan GP; Conover MS; Love CF; Mattoo S; Kock ND; Deora R
Infect Immun; 2010 May; 78(5):2008-16. PubMed ID: 20176797
[TBL] [Abstract][Full Text] [Related]
32. Serum reactome induced by Bordetella pertussis infection and Pertussis vaccines: qualitative differences in serum antibody recognition patterns revealed by peptide microarray analysis.
Valentini D; Ferrara G; Advani R; Hallander HO; Maeurer MJ
BMC Immunol; 2015 Jul; 16():40. PubMed ID: 26129684
[TBL] [Abstract][Full Text] [Related]
33. [Modern strains of Bordetella pertussis: immunobiological properties and vaccine improvement].
Shinkarev AS; Mertsalova NU; Mazurova IK; Borisova OIu; Zakharova NS; Ozeretskovskaia MN; Zaĭtsev EM; Poddubikov AV; Britsina MV; Bazhanova IG
Zh Mikrobiol Epidemiol Immunobiol; 2007; (4):20-5. PubMed ID: 17886371
[TBL] [Abstract][Full Text] [Related]
34. B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial.
Jahnmatz M; Amu S; Ljungman M; Wehlin L; Chiodi F; Mielcarek N; Locht C; Thorstensson R
Vaccine; 2014 Jun; 32(27):3350-6. PubMed ID: 24793938
[TBL] [Abstract][Full Text] [Related]
35. Serospecific protection of mice against intranasal infection with Bordetella pertussis.
Robinson A; Gorringe AR; Funnell SG; Fernandez M
Vaccine; 1989 Aug; 7(4):321-4. PubMed ID: 2573215
[TBL] [Abstract][Full Text] [Related]
36. Protective effects of vaccines against Bordetella parapertussis in a mouse intranasal challenge model.
Komatsu E; Yamaguchi F; Eguchi M; Watanabe M
Vaccine; 2010 Jun; 28(27):4362-8. PubMed ID: 20438876
[TBL] [Abstract][Full Text] [Related]
37. Pertussis vaccines: state-of-the-art and future trends.
Tefon BE; Özcengiz E; Özcengiz G
Curr Top Med Chem; 2013; 13(20):2581-96. PubMed ID: 24066885
[TBL] [Abstract][Full Text] [Related]
38. A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model.
Skerry CM; Mahon BP
Clin Vaccine Immunol; 2011 Feb; 18(2):187-93. PubMed ID: 21147936
[TBL] [Abstract][Full Text] [Related]
39. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains.
Bottero D; Gaillard ME; Fingermann M; Weltman G; Fernández J; Sisti F; Graieb A; Roberts R; Rico O; Ríos G; Regueira M; Binsztein N; Hozbor D
Clin Vaccine Immunol; 2007 Nov; 14(11):1490-8. PubMed ID: 17699837
[TBL] [Abstract][Full Text] [Related]
40. Early Protection against Pertussis Induced by Live Attenuated
Debrie AS; Mielcarek N; Lecher S; Roux X; Sirard JC; Locht C
J Immunol; 2019 Dec; 203(12):3293-3300. PubMed ID: 31732529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
